SCHEMBL891879

SCHEMBL891879

O=C(O)[C@H](O)Cc1c[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 1.00
KDM4E B2RXH2 3/20 0.70
MAPT P10636 3/20 0.70
KMT2A Q03164 3/20 0.70
MEN1 O00255 2/20 0.70
POLB P06746 2/20 0.70
APAF1 O14727 1/20 0.70
RECQL P46063 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
LMNA P02545 1/20 0.70
MPO P05164 1/20 0.70
TSHR P16473 1/20 0.70
BLM P54132 1/20 0.70
PMP22 Q01453 1/20 0.70
HIF1A Q16665 1/20 0.70
ALOX15 P16050 1/20 0.61
DNMT1 P26358 3/20 0.60
CYP2C19 P33261 1/20 0.59
DNMT3B Q9UBC3 1/20 0.59
PKM P14618 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30912052 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL1362995 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL29361050 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL29556806 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL578606 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL30833074 0.89 SMN1; SMN2 (0.81) SMN1; SMN2KDM4EMAPTKMT2AMEN1
Cystine SCHEMBL30036693 0.87 SMN1; SMN2 (0.76) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL4987528 0.87 SMN1; SMN2 (0.76) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL9449541 0.87 SMN1; SMN2 (0.77) SMN1; SMN2KDM4EMAPTKMT2AMEN1
SCHEMBL29388323 0.86 SMN1; SMN2 (0.74) SMN1; SMN2KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968272-B1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2021-06-16 EP disclosed
EP-2968272-B1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORP (US) 2021-06-16 EP disclosed
US-10653670-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2020-05-19 US disclosed
US-10653670-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2020-05-19 US disclosed
US-20190290613-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2019-09-26 US disclosed
US-20190290613-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION 2019-09-26 US disclosed
US-10329575-B2 Regulatory sequence for plants CERES, INC. (US) 2019-06-25 US disclosed
US-10258605-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2019-04-16 US disclosed
US-10258605-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening ALEVERE MEDICAL CORPORATION (US) 2019-04-16 US disclosed
CN-105624228-B A kind of method of microorganism conversion 江南大学 2019-03-15 CN disclosed
WO-2014143125-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING ALEVERE MEDICAL CORPORATION (US) 2014-09-18 WO disclosed
US-20120159672-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. 2012-06-21 US disclosed
US-20120084885-A1 Promoter, promoter control elements, and combinations, and uses thereof ALEXANDROV NICKOLAI (US) 2012-04-05 US disclosed
US-20110191912-A1 Promoter, promoter control elements, and combinations, and uses thereof ALEXANDROV NICKOLAI 2011-08-04 US disclosed
US-20100037355-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY CERES, INC (US) 2010-02-11 US disclosed
US-20090265815-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded therapy ALEXANDROV NICKOLAI 2009-10-22 US disclosed
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. (US) 2007-09-13 US disclosed
US-20060150283-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-07-06 US disclosed
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-03-02 US disclosed
US-6921758-B2 Amino acid derivatives ASTRAZENECA AB (SE) 2005-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120084885-A1 Promoter, promoter control elements, and combinations, and uses thereof RNGTT, GTF3C5, GTF3C1 SMN1; SMN2 4782/4885KDM4E 3381/4885MAPT 3578/4885
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 SMN1; SMN2 4797/4885KDM4E 4418/4885MAPT 3400/4885
US-20110191912-A1 Promoter, promoter control elements, and combinations, and uses thereof RNGTT, GTF3C5, GTF3C1 SMN1; SMN2 4777/4885KDM4E 3374/4885MAPT 3520/4885
US-20190290613-A1 USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING IDO1, FABP4, IDO2 SMN1; SMN2 4435/4885KDM4E 158/4885MAPT 2835/4885
US-20120159672-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 SMN1; SMN2 4797/4885KDM4E 4418/4885MAPT 3400/4885
US-10653670-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening IDO1, FABP4, IDO2 SMN1; SMN2 4435/4885KDM4E 158/4885MAPT 2835/4885
US-20100037355-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY RNGTT, CPSF1, CPSF6 SMN1; SMN2 4797/4885KDM4E 4418/4885MAPT 3400/4885
US-10258605-B2 Use of indole compounds for fat reduction and skin and soft tissue tightening IDO1, FABP4, IDO2 SMN1; SMN2 4435/4885KDM4E 158/4885MAPT 2835/4885
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 SMN1; SMN2 4797/4885KDM4E 4418/4885MAPT 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.